x
Filter:
Filters applied
- ACMG Statements and Guidelines
- Gregg, Anthony RRemove Gregg, Anthony R filter
- Klugman, SusanRemove Klugman, Susan filter
Publication Date
Please choose a date range between 2016 and 2022.
ACMG Statements and Guidelines
These online statements and guidelines are definitive and may be cited using the digital object identifier (DOI). These recommendations are designed primarily as an educational resource for medical geneticists and other healthcare providers to help them provide quality medical genetics services; they should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. Please refer to the leading disclaimer in each document for more information.
3 Results
- Letter to the Editor
Response to Righetti et al
Genetics in MedicineVol. 24Issue 5p1162–1163Published online: February 24, 2022- Jeffrey S. Dungan
- Mahmoud Aarabi
- Susan Klugman
- Anthony R. Gregg
Cited in Scopus: 0We thank Righetti et al1 for their interest in our article titled Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG).2 We were pleased to learn that the investigators from the Australian Reproductive Genetic Carrier Screening Project (ARGCSP) are in agreement with many aspects of this practice resource. - ACMG Practice ResourceOpen Archive
Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG)
Genetics in MedicineVol. 23Issue 10p1793–1806Published in issue: October, 2021- Anthony R. Gregg
- Mahmoud Aarabi
- Susan Klugman
- Natalia T. Leach
- Michael T. Bashford
- Tamar Goldwaser
- and others
Cited in Scopus: 68Carrier screening began 50 years ago with screening for conditions that have a high prevalence in defined racial/ethnic groups (e.g., Tay–Sachs disease in the Ashkenazi Jewish population; sickle cell disease in Black individuals). Cystic fibrosis was the first medical condition for which panethnic screening was recommended, followed by spinal muscular atrophy. Next-generation sequencing allows low cost and high throughput identification of sequence variants across many genes simultaneously. Since the phrase “expanded carrier screening” is nonspecific, there is a need to define carrier screening processes in a way that will allow equitable opportunity for patients to learn their reproductive risks using next-generation sequencing technology. - ACMG StatementOpen Access
Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics
Genetics in MedicineVol. 18Issue 10p1056–1065Published in issue: October, 2016- Anthony R. Gregg
- Brian G. Skotko
- Judith L. Benkendorf
- Kristin G. Monaghan
- Komal Bajaj
- Robert G. Best
- and others
Cited in Scopus: 440Disclaimer: This statement is designed primarily as an educational resource for clinicians to help them provide quality medical services. Adherence to this statement is completely voluntary and does not necessarily assure a successful medical outcome. This statement should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed toward obtaining the same results. In determining the propriety of any specific procedure or test, the clinician should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.